Market World Gastroesophageal Reflux Disease Therapeutics | Page 2

The devices of GERD serves as a substitute for management of heartburn, because of low rate of success and
failure in clinical trials. Hence, very limited acceptance of devices of GERD management contribute for the rising
demand of drugs having acid neutralizing property, as the major therapy approach.
Nevertheless, the advent of devices which are minimally invasive to address anatomical defects are gaining
popularity coupled with supportive evidence from clinical data for performing various procedures including
trans oral fundoplication, which helps in preventing reflux of non-acid and acid contents. The adoption of these
devices have been further reinforced in the U.S. in 2016 with the advent of a CPT code (43210) which helps in
facilitating reimbursement process.
Drug Type Insights
In 2016, market was dominated by the antacids segment and is anticipated to keep its top position over the
forecast period. Most preferred first-line therapy for infrequent and mild symptoms is antacids, as the therapy
neutralize the secretion of gastric acid immediately. Convenient OTC (over-the-counter) accessibility various
forms such as syrups, powders and tablets is accountable for the extreme adoption. Moreover, the AHFS
(American Hospital Formulary services), amongst other countries, enlisted over 120 preparations too advocate.
In 2016, the second largest segment was found to be PPIs as it is the most common medication prescription
type for the diseases such as heartburn. Generics inflow leading to the loss of exclusiveness of popular drugs,
including Prilosec and Nexium, is estimated to negatively affect the sales of branded versions. A further decrease
is appearing more with the expected expiration of other patented drugs, such as Dexilant.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/gastroesophageal-reflux-disease-gerd-therapeutics-market
Regional Insights
In 2016, the largest region was found to be North America in terms of share for GERD market. Every year, GERD
symptoms are experienced by more than 80 million people in the U.S., of which, approximately 25 million
patients suffer from acid reflux and heartburn daily and approximately 60 million patients monthly.
Moreover, outpatient clinic visits for GERD disorder in the U.S. has been increased in the past few years because
of the more prone geriatric population to develop acid reflux and heartburn. On the contrary, the Asia Pacific is
estimated to witness the fastest growth rate. The increasing geriatric population and dietary and lifestyle risk
factors such as diet with high fat and obesity, is anticipated to drive the growth. In developing countries, the
inclination towards self-medication is quickly increasing because of the affordability and availability of OTC
antacids as in China and India.